China Gene sequencing company Shenzhen Huada Gene Co., Ltd. (Huada Gene) net profit fell sharply in the first quarter of this year.The market demand is derived from retreat.
According to the surging news report, the quarterly report released by Huada Gene on Tuesday (April 25) shows that the company realized revenue of 954 million yuan in the first quarter (RMB, the same below, about 180 million yuan), Year -on -year decreased by 33.31%; net profit was about 41.34 million yuan, a year -on -year decrease of 87.49%; net profit attributable to the mother was about 31.15 million yuan, a year -on -year decrease of 89.73%.
Although the BGI did not announce the revenue of the product, the business split the business into "conventional business" and "unconventional business" in the quarterly report to classify and explain.According to Washinga Gene, the reason why the overall operating income decreased by more than 30 % year -on -year in the first quarter was mainly due to the impact of unconventional business operating income due to the macro environment and industry cycle demand decreased significantly compared with the same period of 2022.Further explanation in the reason for the sharp decline in net profit, mainly due to the end of the global public health incident, and the market demand at home and abroad has faded from the surge in domestic and foreign.
Data show that the revenue of Washinga Gene mainly comes from comprehensive solutions of precision medical testing, basic research and clinical application services, basic research and clinical application services, tumor prevention and control and transformation medicineFive major businesses such as class services, multiple groups of big data services and synthetic businesses.Among them, the business -related business is summarized in the comprehensive solution of the testing plan sector of precision medicine. It is the largest business of Huada Gene and has fluctuated in more than three years.
The financial report of the year shows that the 2019 revenue of precision medicine to solve the detection plan section was 571 million yuan in 2019, and the revenue contribution was 20.4%; in 2020, the outbreak of the business revenue increased to 5.562 billion yuan, and the campThe contribution reached 66.24%; in 2021, the business revenue fell to 3.382 billion yuan, and the revenue contribution dropped to 49.99%.By 2022, due to the adjustment of the policies of the crown disease and the increasing market competition, the nucleic acid testing services and the unit price of reagents will continue to decline, which will further reduce the revenue of the business to about 2.5 billion yuan, and the revenue contribution will be simultaneously dropped to about 35.54%.
In addition, the decline in net profit is also related to the high cost.The financial report shows that the net profit of the mother in the first quarter of 2023 has been lower than the same time in 2019.Huada Gene also emphasized in the quarterly report that after the contraction of the uninvited business, the relevant cost adjustment requires a certain period. The company will continue to strengthen internal lean management, optimize the organizational structure, and reduce the cost of sales management.
As of the close of Tuesday, Huada Gene reported at 65.05 yuan, down 2.58%; since this year, the stock price of Huada gene has risen by 25.85%.
